{
    "clinical_study": {
        "@rank": "28573", 
        "arm_group": {
            "arm_group_label": "Lucitanib", 
            "arm_group_type": "Experimental", 
            "description": "Lucitanib given orally once daily on a continuous schedule. Starting dose 15 mg/day"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether lucitanib is effective in the treatment of\n      patients with FGFR1 amplified squamous non-small cell lung cancer."
        }, 
        "brief_title": "A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Squamous NSCLC", 
            "Squamous Non-small Cell Lung Cancer", 
            "Non-small Cell Lung Cancer", 
            "Stage IV Lung Cancer", 
            "Lung Cancer", 
            "Metastatic Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Lucitanib is an oral inhibitor of the tyrosine kinase activity of FGFR 1/2 and VEGFR 1-3.\n      Lucitanib has demonstrated potent antitumour and antiangiogenic activity in several\n      preclinical models of cancer, including a human lung cancer model (H1581) which harbors\n      FGFR1 amplification.\n\n      The first in human trial of lucitanib demonstrated that 15 mg of lucitanib given daily, can\n      provide durable clinical responses in cancer patients with alterations of the FGF pathway.\n      Based on these results, lucitanib is being studied in FGFR1 amplified squamous non-small\n      cell lung cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed stage IV squamous NSCLC\n\n          -  FGFR1-amplification determined on the most recent archive sample available or on a\n             newly performed biopsy\n\n          -  Availability of a tissue sample suitable for the central confirmation by FISH of\n             FGFR1 amplification\n\n          -  Eastern Cooperative Oncology Group (ECOG) of 0 or 1\n\n          -  Measurable disease per RECIST 1.1\n\n          -  At least one prior treatment line in the advanced-metastatic setting\n\n          -  Ability to take oral medication\n\n        Exclusion Criteria:\n\n          -  Symptomatic and/or untreated central nervous system metastases\n\n          -  Presence of another active cancer\n\n          -  Biologic therapy, chemotherapy, radiation, or surgery within 4 weeks of the first\n             dose of Lucitanib"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02109016", 
            "org_study_id": "E-3810-II-02"
        }, 
        "intervention": {
            "arm_group_label": "Lucitanib", 
            "description": "Lucitanib given orally to all patients. once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior and 2 hours after any meal), until progressive disease or unacceptable toxicity.\nStarting dose is 15 mg/day and can be reduced at 2.5 mg steps till 7.5 mg/day based on individual tolerability.", 
            "intervention_name": "Lucitanib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "FGFR-1 amplification", 
            "Tyrosine kinase inhibitor", 
            "VEGFR inhibitor", 
            "FGFR inhibitor", 
            "VEGRF-FGFR inhibitor"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Single Arm, Open-label, Phase II Study to Assess the Efficacy of the Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, Lucitanib, Given Orally as a Single Agent to Patients With FGFR1-driven Lung Cancer", 
        "overall_contact": {
            "email": "clinicaltrialinfo@clovisoncology.com", 
            "last_name": "Clovis Oncology Clinical Trial Information"
        }, 
        "overall_official": {
            "affiliation": "Clovis Oncology, Inc.", 
            "last_name": "Jason B Litten, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "France: Ministry of Health", 
                "Germany: Ministry of Health", 
                "Italy: Ministry of Health", 
                "Spain: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of patients in whom a confirmed Complete Response (CR) or a confirmed Partial Response (PR), as best overall response according to RECIST criteria, is observed.", 
            "measure": "Objective Response Rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "Screening, every 8 weeks; up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02109016"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of patients in whom a confirmed CR or confirmed PR or a prolonged Stable Disease (SD) (\u2265 6 months), as best overall response according to RECIST, is observed", 
                "measure": "Clinical Benefit Rate (CBR)", 
                "safety_issue": "No", 
                "time_frame": "Screening, every 8 weeks; up to 2 years"
            }, 
            {
                "description": "Time from the date of first drug intake until the date of progression or death for any cause", 
                "measure": "Progression-Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Screening, every 8 weeks; up to 2 years"
            }, 
            {
                "description": "For responders (i.e. patients with best overall response CR or PR), the interval from the time of first documentation of response to the date of progression or death for any cause", 
                "measure": "Duration of response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "Screening, every 8 weeks; up to 2 years"
            }, 
            {
                "description": "For responders and patients with SD as best overall response, time from the first drug intake until the date of progression or death for any cause", 
                "measure": "Duration of clinical benefit", 
                "safety_issue": "No", 
                "time_frame": "Screening, every 8 weeks; up to 2 years"
            }, 
            {
                "description": "From the date of first drug intake to the date of death for any cause", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Continuously; up to 2 years"
            }, 
            {
                "description": "Will be evaluated using the following criteria:\nThe tumour size defined as the sum of the largest diameters of target lesions\nThe tumour volume\nThe Tumour Growth rate defined as an increase in tumour volume during 1 month", 
                "measure": "Tumour growth kinetics", 
                "safety_issue": "No", 
                "time_frame": "Screening, every 8 weeks; up to 2 years"
            }, 
            {
                "measure": "Incidence of adverse events (AEs), clinical laboratory abnormalities, and dose modifications", 
                "safety_issue": "Yes", 
                "time_frame": "Continuously; up to 2 years"
            }, 
            {
                "measure": "PK parameters of Lucitanib", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 14 and  28, Cycle 2 Day 56, Cycle 3 Day 84"
            }, 
            {
                "measure": "Pharmacogenomic approach of inter-patients variation in gene encoding ADME involved proteins", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 1"
            }, 
            {
                "description": "Soluble growth factors and other biomarkers, including circulating tumour DNA", 
                "measure": "Pharmacodynamics (PD)", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 1"
            }
        ], 
        "source": "Clovis Oncology, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Clovis Oncology, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}